Current Allergy and Asthma Reports

, Volume 6, Issue 3, pp 232–238 | Cite as

RETRACTED ARTICLE: Treating allergic rhinitis in pregnancy

  • Vincent Piette
  • Jean-Pierre Daures
  • Pascal Demoly
Article

Abstract

Numerous pregnant women suffer from allergic rhinitis, and particular attention is required when prescribing drugs to these patients. In addition, physiologic changes associated with pregnancy could affect the upper airways. Evidence-based guidelines on the management of allergic rhinitis have been published. Medication can be prescribed during pregnancy when the apparent benefit of the drug is greater than the apparent risk. Usually, there is at least one "safe" drug from each major class used to control symptoms. All glucocorticosteroids are teratogenic in animals but, when the indication is clear (for diseases possibly associated, such as severe asthma exacerbation), the benefit of the drug is far greater than the risk. Inhaled glucocorticosteroids (eg, beclomethasone or budesonide) have not been incriminated as teratogens in humans and are used by pregnant women who have asthma. A few H1-antihistamines can safely be used as well. Most oral decongestants (except pseudoephedrine) are teratogenic in animals. There are no such data available for intranasal decongestants. Finally, pregnancy is not considered to be a contraindication for the continuation of immunotherapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Incaudo GA: Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation. Clin Rev Allergy Immunol 2004, 27:159–177.PubMedCrossRefGoogle Scholar
  2. 2.
    Ellegard EK: Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol 2004, 26:149–159.PubMedCrossRefGoogle Scholar
  3. 3.
    Blaiss MS, Food and Drug Administration (U.S.); ACA AI-ACOG (American College of Allerg y, Asthma, and Immunolog y and American College of Obstetricians and Gynecologists): Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol 2003, 90:S16-S22.CrossRefGoogle Scholar
  4. 4.
    Schatz M: Special considerations for the pregnant woman and senior citizen with airway disease. J Allergy Clin Immunol 1998, 101:S373-S378.PubMedCrossRefGoogle Scholar
  5. 5.
    Mazzotta P, Loebstein R, Koren G: Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf 1999, 20:361–375.PubMedCrossRefGoogle Scholar
  6. 6.
    Ellegard E, Karlsson G: Nasal congestion during pregnancy. Clin Otolaryngol 1999, 24:307–311.PubMedCrossRefGoogle Scholar
  7. 7.
    Ellegard E, Karlsson G: IgE-mediated reactions and hyperreactivity in pregnancy rhinitis. Arch Otolaryngol Head Neck Surg 1999, 125:1121–1125.PubMedCrossRefGoogle Scholar
  8. 8.
    Sorri M, Hartikainen-Sorri AL, Karja J: Rhinitis during pregnancy. Rhinology 1980, 18:83–86.PubMedGoogle Scholar
  9. 9.
    Miyake Y, Miyamoto S, Ohya Y, et al.: Association of active and passive smoking with allergic disorders in pregnant Japanese women: baseline data from the Osaka Maternal and Child Health Study. Osaka Maternal and Child Health Study Group. Ann Allergy Asthma Immunol 2005, 94:644–651.PubMedCrossRefGoogle Scholar
  10. 10.
    Miyake Y, Sasaki S, Ohya Y, et al.: Soy, isoflavones, and prevalence of allergic rhinitis in Japanese women: the Osaka Maternal and Child Health Study. J Allergy Clin Immunol 2005, 115:1176–1183. In this cross-sectional study involving more than 1000 pregnant women, a high intake of soy and isof lavones was associated with a reduced prevalence of allergic rhinitis. This may give some insight for dietar y prevention of allergic rhinitis during pregnancy.PubMedCrossRefGoogle Scholar
  11. 11.
    Forastiere F, Sunyer J, Farchi S, et al.: Number of offspring and maternal atopy. Allergy 2005, 60:510–514.PubMedCrossRefGoogle Scholar
  12. 12.
    Savilahti E, Siltanen M, Pekkanen J, Kajosaari M: Mothers of very low birth weight infants have less atopy than mothers of full-term infants. Clin Exp Allergy 2004, 34:1851–1854.PubMedCrossRefGoogle Scholar
  13. 13.
    Brooks K, Samms-Vaughan M, Karmaus W: Are oral contraceptive use and pregnancy complications risk factors for atopic disorders among offspring? Pediatr Allergy Immunol 2004, 15:487–496.PubMedCrossRefGoogle Scholar
  14. 14.
    Philpott CM, Conboy P, Al-Azzawi F, Murty G: Nasal physiological changes during pregnancy. Clin Otolaryngol Allied Sci 2004, 29:343–351.PubMedCrossRefGoogle Scholar
  15. 15.
    Bousquet J, van-Cauwenberge P, Khaltaev N, WHO Panel Members: Allergic rhinitis and its impact on asthma. ARIA. In collaboration with the World Health Organization. J Allergy Clin Immunol 2001, 108:S1-S315.CrossRefGoogle Scholar
  16. 16.
    Kusanagi T: Occurrence of cleft palate, palatal slit, and fetal death in mice treated with a glucocorticoid: an embryo transfer experiment. Teratology 1983, 27:395–400.PubMedCrossRefGoogle Scholar
  17. 17.
    Park-Wyllie L, Mazzotta P, Pastuszak A, et al.: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62:385–392.PubMedCrossRefGoogle Scholar
  18. 18.
    Reinisch JM, Simon NG, Karow WG, Gandelman R: Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978, 202:436–438.PubMedCrossRefGoogle Scholar
  19. 19.
    Schatz M, Zeiger RS, Harden K, et al.: The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997, 100:301–306.PubMedCrossRefGoogle Scholar
  20. 20.
    Schatz M, Patterson R, Zeitz S, et al.: Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975, 233:804–807.PubMedCrossRefGoogle Scholar
  21. 21.
    Snyder RD, Snyder D: Corticosteroids for asthma during pregnancy. Ann Allergy 1978, 41:340–341.PubMedGoogle Scholar
  22. 22.
    Ellegard EK, Hellgren M, Karlsson NG: Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol 2001, 26:394–400.PubMedCrossRefGoogle Scholar
  23. 23.
    Cave A, Arlett P, Lee E: Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999, 83:153–179.PubMedCrossRefGoogle Scholar
  24. 24.
    Greenberger PA, Patterson R: Beclomethasone diproprionate for severe asthma during pregnancy. Ann Intern Med 1983, 98:478–480.PubMedCrossRefGoogle Scholar
  25. 25.
    Briggs GC, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation—a Reference Guide to Fetal and Neonatal Risk, edn 8. Baltimore: Lippincott Williams & Wilkins; 1998.Google Scholar
  26. 26.
    Namazy J, Schatz M, Long L, et al.: Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004, 113:427–432. Most of the asthmatics suffer from rhinitis as well. Therefore, safety studies on inhaled steroids in pregnant asthmatic women are of great interest.PubMedCrossRefGoogle Scholar
  27. 27.
    Stenius-Aarniala BS, Hedman J, Teramo KA: Acute asthma during pregnancy. Thorax 1996, 51:411–414.PubMedCrossRefGoogle Scholar
  28. 28.
    Kallen B, Rydhstroem H, Aberg A: Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999, 93:392–395.PubMedCrossRefGoogle Scholar
  29. 29.
    Kallen BA, Otterblad Olausson P: Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003, 17:255–261.PubMedCrossRefGoogle Scholar
  30. 30.
    Norjavaara E, de VerdierMG: Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003, 111:736–742.PubMedCrossRefGoogle Scholar
  31. 31.
    Gluck PA, Gluck JC: A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin 2005, 21:1075–1084. In this systematic search of the literature indexed on Medline or the Developmental and Reproductive Toxicology (DART) database, the authors found no clinically or statistically significant effects on fetal outcomes among more than 6600 infants whose mothers were exposed to orally inhaled budesonide during pregnancy.PubMedCrossRefGoogle Scholar
  32. 32.
    Orr TS: Mode of action of disodium cromoglycate. Acta Allergol 1977, 13:9–27.PubMedGoogle Scholar
  33. 33.
    Norris A A: Pharmacology of sodium cromoglycate. Clin Exp Allergy 1996, 4:5–7.CrossRefGoogle Scholar
  34. 34.
    Wilson J: Use of sodium cromoglycate during pregnancy. Acta Ther 1982, 8:S45-S51.Google Scholar
  35. 35.
    Gengo FM, Manning C: A review of the effects of antihistamines on mental processes related to automobile driving. J Allergy Clin Immunol 1990, 86:1034–1039.PubMedCrossRefGoogle Scholar
  36. 36.
    Walker BE, Patterson A: Induction of cleft palate in mice by tranquilizers and barbiturates. Teratology 1974, 10:159–163.PubMedCrossRefGoogle Scholar
  37. 37.
    King CT, Howell J: Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol 1966, 95:109–111.PubMedGoogle Scholar
  38. 38.
    Saxen I: Cleft palate and maternal diphenhydramine intake. Lancet 1974, 1:407–408.PubMedCrossRefGoogle Scholar
  39. 39.
    Schatz M, Petitti D: Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997, 78:157–159.PubMedCrossRefGoogle Scholar
  40. 40.
    Ciprandi G, Liccardi G, D’Amato G, et al.: Treatment of allergic diseases during pregnancy. J Investig Allergol Clin Immunol 1997, 7:557–565.PubMedGoogle Scholar
  41. 41.
    Gilbert C, Mazzotta P, Loebstein R, Koren G: Fetal safety of drugs used in the treatment of allergic rhinitis: a clinical review. Drug Saf 2005, 28:707–719. This review lists the many safe treatment options for clinicians treating allergic rhinitis during pregnancy.PubMedCrossRefGoogle Scholar
  42. 42.
    Einarson A, Bailey B, Jung G, et al.: Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997, 78:183–186.PubMedCrossRefGoogle Scholar
  43. 43.
    Keles N: Treatment of allergic rhinitis during pregnancy. Am J Rhinol 2004, 18:23–28.PubMedGoogle Scholar
  44. 44.
    Källén B: Drugs in pregnancy: the dilemma of labeling. Drug Inform J 1999, 33:1135–1143.Google Scholar
  45. 45.
    Nelson HS: Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2004, 113:635–642.PubMedCrossRefGoogle Scholar
  46. 46.
    Diav-Citrin O, Shechtman S, Aharonovich A, et al.: Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003, 111:1239–1243.PubMedCrossRefGoogle Scholar
  47. 47.
    Moretti ME, Caprara D, Coutinho CJ, et al.: Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003, 111:479–483.PubMedCrossRefGoogle Scholar
  48. 48.
    Wood CC, Fireman P, Grossman J, et al.: Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol 1995, 95:1111–1116.PubMedCrossRefGoogle Scholar
  49. 49.
    Malm L: Pharmacological background to decongesting and anti-inflammatory treatment of rhinitis and sinusitis. Acta Otolaryngol Suppl 1994, 515:53–55.PubMedCrossRefGoogle Scholar
  50. 50.
    Johnson DA, Hricik JG: The pharmacology of alphaadrenergic decongestants. Pharmacotherapy 1993, 13:110S-115S.PubMedGoogle Scholar
  51. 51.
    Graf P, Hallen H, Juto JE: Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol 1995, 115:71–75.PubMedCrossRefGoogle Scholar
  52. 52.
    Kanfer I, Dowse R, Vuma V: Pharmacokinetics of oral decongestants. Pharmacotherapy 1993, 13:116S-128S.PubMedGoogle Scholar
  53. 53.
    Bateman DN, McElhatton PR, Dickinson D, et al.: A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England. Eur J Clin Pharmacol 2004, 60:635–641.PubMedCrossRefGoogle Scholar
  54. 54.
    Werler MM, Sheehan JE, Mitchell AA: Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002, 155:26–31.PubMedCrossRefGoogle Scholar
  55. 55.
    Aselton P, Jick H, Milunsky A, et al.: First-trimester drug use and congenital disorders. Obstet Gynecol 1985, 65:451–455.PubMedGoogle Scholar
  56. 56.
    Jick H, Holmes LB, Hunter JR, et al.: First-trimester drug use and congenital disorders. JAMA 1981, 246:343–346.PubMedCrossRefGoogle Scholar
  57. 57.
    The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI): The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol 2000, 84:475–480.CrossRefGoogle Scholar
  58. 58.
    Bousquet J, Lockey R, Malling HJ, WHO Panel Members: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558–562.PubMedCrossRefGoogle Scholar
  59. 59.
    Metzger WJ, Turner E, Patterson R: The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978, 61:268–272.PubMedCrossRefGoogle Scholar
  60. 60.
    Morgan WJ, Crain EF, Gruchalla RS, et al.: Inner-City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004, 351:1068–1080.PubMedCrossRefGoogle Scholar
  61. 61.
    Nuutinen J, Holopainen E, Haahtela T, et al.: Balanced physiological saline in the treatment of chronic rhinitis. Rhinology 1986, 24:265–269.PubMedGoogle Scholar
  62. 62.
    Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998, 317:1624–1629.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Vincent Piette
  • Jean-Pierre Daures
  • Pascal Demoly
    • 1
  1. 1.Exploration des Allergies-Maladies Respiratoires—INSERM U454, Höpital Arnaud de VilleneuveUniversity Hospital of MontpellierMontpellier Cedex 5France

Personalised recommendations